Labcorp Buys MLM Medical Labs to Boost Global Trial Capabilities
LH sits 34% above its 52-week low of $244.52.
Summary
Labcorp is acquiring MLM Medical Labs, a move that expands its global central laboratory and biomarker capabilities for clinical trials. The deal strengthens Labcorp's position in the high-growth clinical trial services market, adding specialized biomarker testing and international reach. This follows a series of strategic moves including the launch of the Marker genetic testing platform and FDA approval for PGDx Elio Tissue Complete CDx. The acquisition is likely to enhance Labcorp's competitive edge in supporting drug development, though financial terms were not disclosed. Investors will watch for integration details and any impact on margins at the upcoming Investor Day on September 10.
At the time of this announcement, LH was trading at $326.68 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26.5B. The 52-week trading range was $244.52 to $341.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.